Renovite's founder and chief executive Viren Rana called JPMorgan's payments division a "natural home" for the company's people and technology
The European Union's anti-trust watchdog announced on Tuesday that it is blocking the buyout of cancer-screening company GRAIL by biotech giant Illumina in a rare move by European regulators against two US companies. Illumina is a major supplier of next-generation sequencing (NGS) systems for genetic and genomic analysis, while GRAIL is a health company developing blood tests to try to catch cancer early. Illumina announced an $8 billion acquisition of GRAIL in 2020. But the European Commission, which polices competition issues, said the buyout would have enabled and incentivised Illumina to foreclose GRAIL's rivals, who are dependent on Illumina's technology, from access to an essential input they need to develop and market their own tests. Commission Executive Vice-President Margrethe Vestager said that it is vital to preserve competition between early cancer detection test developers at this critical stage of development. As Illumina did not put forward remedies that would have .
The stock is down 35 per cent this year and is trading at its lowest since July 2020
The tax applies on e-commerce transactions on websites such as Amazon.com
Trump said in a Fox Business Network interview that taxation was an "incentive" for companies to return manufacturing to the United States
In talks with Medtronic and Abbott on relocating units
"This is one of the areas that I think provides some sense of optimism," the chamber's president, Alan Beebe, said at a news conference accompanying the survey's release
A quarter of larger companies surveyed expressed an intention to invest in India
Oxfam said these 50 companies had an effective rate nearly 10 percentage points lower